Market Access News

Introduction   The Canadian Association for Healthcare Reimbursement (CAHR) held its first virtual Market Access 201 conference on November 24, 2020.  Members of the MORSE team attended this conference and have prepared a brief summary of the key highlights. Disclaimer: Please note, this summary is based on our team’s interpretation of the discussion.   Session 1. Keynote: Evolution of HTA in United States and the Impact on International Markets  …

pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights   October 2020 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 5 new recommendations in October (22 files as of October 31). PRODUCT INDICATION SPONSOR Type REC’N* DATE Xtandi** (enzalutamide) Metastatic…

pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights   September 2020 Highlights: 1 product completed CADTH review 0 products initiated pCPA negotiations 2 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation   Files Under pCPA Consideration: CADTH issued 1 new recommendation in September (25 files as of September 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Zejula (niraparib) Ovarian…

pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights   August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Soliris (eculizumab) Neuromyelitis…

pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights   July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start…

pan-Canadian Pharmaceutical Alliance (pCPA): June 2020 Trends and Insights   June Highlights: 4 products completed CADTH review 7 products initiated pCPA negotiations 4 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation   Files Under pCPA Consideration: CADTH issued 4 new recommendations in June (23 files as of June 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Cuvposa (glycopyrrolate) Chronic severe…

Consultations on Enhanced and Aligned Review Processes and Program Updates.   CADTH released its Pharmaceutical Reviews Update — Issue 16 on June 25, 2020. It includes two consultations with respect to enhanced and aligned review processes, in addition to program update announcements. Highlights of the consultations and program updates are described below.   Topic MORSE Note Consultations – Feedback due to CADTH by August 10, 2020 Consultation on Alignment of…

pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights   May Highlights: 8 products completed CADTH review 5 products initiated pCPA negotiations 0 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation.  No negotiations were completed or closed for the first…

pan-Canadian Pharmaceutical Alliance (pCPA): April 2020 Trends and Insights   April Highlights: 6 products completed CADTH review 4 products initiated pCPA negotiations 11 negotiations were completed with an LOI 2 negotiations were closed without an LOI 2 files were closed without negotiation In keeping with pCPA’s communication to industry associations, early trends into their management of files during the challenges associated with COVID indicate that initial priority has been on…

CADTH recently released their annual business plan for 2020-2021. In this, the last year of their three-year strategic plan, CADTH aims to deliver on a number of priority initiatives, several of which may have implications for industry, as described below.   1) Operationalize the Life Cycle Approach to Health Technology Assessment (HTA) Under this priority initiative, CADTH signals their continued commitment to the life cycle approach to HTA via: enhancement…

CADTH released its Pharmaceutical Reviews Update — Issue 15 on April 29, 2020.  Please find below MORSE Consulting’s summary of this update. Topic MORSE Note 1. COVID-19 Update CADTH will continue to deliver on core activities, including the completion of ongoing drug reviews and initiation of new reviews in accordance with target timelines, and progress reports will continue to be posted on the CADTH website. Pre-submission and expert committee meetings…

pan-Canadian Pharmaceutical Alliance (pCPA): March 2020 Trends and Insights   The pan-Canadian Pharmaceutical Alliance (pCPA) has launched a new website (https://www.pcpacanada.ca) with searchable data regarding brand name drug negotiations status and highlighting pCPA activity in the last four weeks. Highlights of the pCPA activity in March are: 5 products completed CADTH review, for a total of 16 files under consideration; 2 products initiated pCPA negotiations, for a total of 29…

pan-Canadian Pharmaceutical Alliance (pCPA): February 2020 Trends and Insights   Due to the COVID-19 outbreak, the pCPA is implementing measures to work within the current reality while still attempting to meet its mandate. Consequently, some existing negotiations may be delayed or temporarily halted while the negotiating jurisdiction focuses on responding to the COVID-19 situation. The pan-Canadian Pharmaceutical Alliance (pCPA) has issued the February 29, 2020 status of brand negotiations.  Highlights…